BioTech Funding Portal Review 2026: Two Proposed Raises, No Live Offerings
BioTech Funding Portal (biotech.fund) is a Regulation Crowdfunding portal only for life-science companies, open to accredited and non-accredited investors with minimums from $500. It filed its funding portal registration in November 2024 and announced its public launch on June 22, 2026; as of November 9, 2026 no company has filed an offering through it. Its offerings page lists two drug developers Testing the Waters, each proposing a $1 million raise on a SAFE: Glafabra Therapeutics (Fabry disease; $12 million cap, 20% discount, $1,000 minimum) and Energesis Pharmaceuticals (obesity; CrowdSAFE, $500 minimum). The terms are preliminary and the listings accept only expressions of interest. A fictional demo company sits beside them. Investors pay no portal fee; issuers' fees will appear in each Form C.
No platform response on record for this review. Is this your platform? Respond or claim it.
What the data actually shows - TL;DR
BioTech Funding Portal is a niche version of Wefunder or StartEngine: a funding portal where US life-science companies (drugs, devices, diagnostics, veterinary products) can raise up to $5 million a year from the public under Regulation Crowdfunding, with each raise filed on a Form C and investor money held in third-party escrow until the company hits its minimum. It is run by BioTech Funding Portal LLC of Chicago, a subsidiary of BioTech Social, Inc., founded by neuroscientist Dr. Neva West (CEO) and crowdfunding-industry executive Brian Christie (chair).
Read the full assessmentShow less
The registration is real and current: the CFPORTAL was filed November 8, 2024, FINRA's directory lists the portal (SEC file 7-474), and BioTech Social announced the public launch on June 22, 2026. No Form C has named the portal yet, so no offering has opened and no investor has bought anything through it. What it shows today are two companies Testing the Waters, a stage at which investors can only submit non-binding expressions of interest, beside a fictional demo issuer on the same page.
The listings are detailed and sourced (an FDA orphan designation for Glafabra; preclinical obesity data for Energesis), and both show proposed terms: Glafabra lists a proposed $1 million raise on a SAFE with a $12 million valuation cap, a 20% discount and a $1,000 minimum; Energesis lists a proposed $1 million CrowdSAFE with a $500 minimum, converting at what the listing calls 'the better of a $13M-$15M cap or 20% discount'. The listing does not explain the cap range. These are preliminary terms; the binding ones arrive with a Form C. Investors pay no portal fee; the portal may be paid by issuers in cash or in the issuers' own securities, and pays $3,141 to anyone who refers a company that files a Form C through it, launches its offering and stays live and in good standing for 90 days.
EDGAR full-text search finds no Form C, amendment, progress update or annual report naming BioTech Funding Portal, BioTech Social or biotech.fund from 2020 to November 9, 2026. The portal filed its CFPORTAL on November 8, 2024, renamed itself in April 2025 and announced its public launch on June 22, 2026; no offering has been filed through it.
The offerings page shows Glafabra Therapeutics (proposed $1 million SAFE, $12 million cap, 20% discount, $1,000 minimum) and Energesis Pharmaceuticals (proposed $1 million CrowdSAFE, 'better of a $13M-$15M cap or 20% discount', $500 minimum), both 'Testing the Waters (EOIs)', and PawNoma Bio, labelled a fictional demo for educational purposes. The terms are preliminary. During testing the waters 'you cannot invest and no funds are collected'; expressions of interest are non-binding.
'BFP does not charge fees to investors directly for investing', though vendor costs can be passed through (for example 3.5% for credit cards). Issuers pay portal fees 'tied to funds raised and/or securities issued'; the CFPORTAL allows payment 'in cash and/or securities of the issuer'. The actual terms will be in each Form C; no schedule is published.
SEC-registered funding portal and FINRA member, listed in FINRA's funding portal directory (SEC file 7-474), with North Capital Private Securities Corporation named as escrow agent. Its registration answers every disciplinary question No, and AltStreet found no court case or regulatory action naming the portal, its parent or its officers.
The parent, BioTech Social, Inc., reported $275,000 sold of a $1.5 million convertible debt offering to 2 investors on its January 2025 Form D (Rule 506(b), first sale April 16, 2024). No later raise by the parent appears on EDGAR.
Filing facts are from EDGAR as filed. Listing content is the companies' own, as hosted by the portal. 'No offering' means no Form C naming the portal was found by EDGAR full-text search through November 9, 2026.
Visual Summary
What is on the portal
Listings as captured November 9, 2026; filing facts from EDGAR.
Glafabra Therapeutics (Fabry disease cell therapy)
Proposed $1M SAFE, $12M cap, 20% discount, $1,000 minimum; Testing the Waters (interest only); FDA orphan designation March 2026; no Form C
Energesis Pharmaceuticals (obesity, brown fat)
Proposed $1M CrowdSAFE, 'better of a $13M-$15M cap or 20% discount', $500 minimum; Testing the Waters (interest only); preclinical; no Form C
PawNoma Bio
Fictional demo issuer; nothing offered
Form C filings naming the portal
None found through November 9, 2026 (public launch June 22, 2026)
Parent capital (BioTech Social, Inc.)
$275,000 of $1.5 million convertible debt, 2 investors (Form D, January 2025)
Quick Verdict
Is this platform right for you?
BioTech Funding Portal is a properly registered Reg CF portal with a sensible niche, detailed listings and investor-friendly terms on paper (no investor fee, third-party escrow, clear FAQs). It has no track record yet: since its June 2026 launch it has not hosted a filed offering, and its two real listings, each proposing a $1 million SAFE raise (Glafabra at a $12 million cap and 20% discount; Energesis at 'the better of a $13M-$15M cap or 20% discount'), are still collecting non-binding interest. For now it is a place to follow biotech programs, not to invest; when the first Form C is filed, read it on EDGAR, including what the portal is paid and whether it takes the issuer's stock.
Best for
- Biotech-interested retail investors willing to wait for the first offerings
- Patients and advocates following specific programs
Avoid if
- You want to invest now
- You need liquidity or income
- You cannot afford to lose the whole amount
Top strengths
- SEC-registered funding portal and FINRA member, with third-party escrow
- No portal fee for investors
- Listings carry development-stage trackers with sources (trial numbers, publications, FDA designations)
- Clear terms and FAQs, including testing-the-waters rules
Key limitations
- No offering filed or closed since the June 2026 launch
- No issuer fee schedule; the portal may be paid in issuers' securities
- A fictional demo issuer appears beside the real listings
- Listing copy that conflicts with its own tracker (Glafabra); an unexplained cap range (Energesis)
- Small parent: $275,000 of convertible debt reported
Compare Before Deciding
Where BioTech Funding Portal fits against alternatives
Use these hooks to pressure-test whether this is the right platform, or whether a nearby alternative matches the job better.
How this compares to VitaDAO
VitaDAO
A token-governed collective funding longevity research.
How this compares to Wefunder
Wefunder
The largest general Reg CF portal, with a long offering record.
How this compares to Vicinity
Vicinity
A regional Reg CF portal with a funded record and reporting gaps.
0
Offerings filed through the portal
No Form C names it, November 2024 to November 9, 2026.
2
Companies Testing the Waters
Glafabra and Energesis; interest only, no money accepted.
$0
Portal fee to investors
Pass-through costs only, such as 3.5% for card payments.
#334156
FINRA funding portal number
SEC-registered since November 8, 2024; escrow with North Capital.
Quick Answers
What most investors want to know first
The highest-signal facts first: minimums, liquidity reality, K-1 timing, and whether distributions are actually part of the experience.
Liquidity
None on the portal.
K-1 Timing
Issuer-specific.
Distributions
None expected from pre-revenue drug developers.
Overview
Platform Overview
A concise read on what the platform is, how the structure works, and where the practical friction shows up for real investors.
BioTech Funding Portal LLC (Delaware, formed July 22, 2024; Chicago) operates biotech.fund, a Regulation Crowdfunding funding portal limited to life-science issuers. Under Reg CF a US company can raise up to $5 million in 12 months from anyone over 18, with non-accredited investors capped by income and net worth; it files a Form C with the SEC describing the company, the security, the price and the use of proceeds; investors commit through the portal, money sits in third-party escrow, and the raise closes only if the minimum target is met, with investors able to cancel up to 48 hours before the deadline. Before filing, a company may 'test the waters', publishing a profile and collecting non-binding expressions of interest; that is the stage both of the portal's real listings are at.
The site also runs a community (profiles by role, a feed, Q&A, posts) built for patients, scientists, clinicians and investors. The parent, BioTech Social, Inc. (Delaware; Rockville, Maryland), owns the site.
Investors pay no portal fee; issuers' fees will be stated in each Form C.
Company and people
BioTech Funding Portal LLC (Chicago), subsidiary of BioTech Social, Inc. (Rockville, MD). Co-founders Dr. Neva West (CEO) and Brian Christie (chair).
Regulation
SEC-registered funding portal and FINRA member (#334156; CIK 2043584); escrow agent North Capital Private Securities Corporation; not a broker-dealer or adviser.
Who can invest
Anyone 18 or older; non-accredited investors subject to Reg CF limits across all portals; minimums set by issuers, from $500.
Fees
None charged to investors beyond pass-through costs (for example 3.5% on card payments). Issuers pay fees tied to funds raised and/or securities issued, stated in each Form C.
Listings (November 9, 2026)
Glafabra Therapeutics (proposed $1M SAFE, $12M cap, 20% discount) and Energesis Pharmaceuticals (proposed $1M CrowdSAFE, $13M-$15M cap or 20% discount), Testing the Waters (non-binding interest only); PawNoma Bio, a fictional demo.
Court and enforcement record
None located for the portal, its parent or its officers; registration disciplinary answers all No.
ASWhat the filings and the site show
- Registered portal, launched June 2026, no offering filed yet.
- Two proposed $1M SAFE raises, preliminary and interest-only.
- Issuer-paid model, possibly in issuer securities.
Key Gaps & Non-Disclosures
- No issuer fee schedule.
- No published diligence results.
- Parent finances beyond the 2025 Form D.
Platform Intelligence
BioTech Funding Portal timeline
Key platform events, regulatory turns, liquidity stress points, and product launches that shape how the review should be read.
Parent raises; portal registers
April: first sale of BioTech Social, Inc.'s convertible debt. July 22: portal LLC formed. November 8: CFPORTAL filed as BioTech Social Crowdfunding Portal LLC.
Renamed; parent Form D
January: BioTech Social reports $275,000 sold to 2 investors. April: portal renamed BioTech Funding Portal LLC and moved to Chicago's Merchandise Mart.
Public launch; Testing the Waters
March: Glafabra receives FDA orphan designation. June 20: terms of use revised. June 22: BioTech Social announces the portal's public launch at the BIO International Convention. November 9: two testing-the-waters listings proposing $1 million SAFE raises, and a demo; no Form C filed through the portal.
Glafabra US target
Glafabra targets an IND filing in mid-2027 and a US trial start in early 2028 (company website); the portal listing's tracker shows 'Target: 2027'.
Investor Operations
The practical questions investors actually care about: when tax documents arrive, how cash distributions work, and whether capital can be exited before the underlying asset is sold.
Tax Documents
K-1 Timing
What to expect
Issuer-specific.
Delay signals
- No offering yet
Extension risk
Not stated.
Confidence: Low
Cash Flow
Distributions
Timing
None expected from pre-revenue drug developers.
Consistency
No offering has closed.
Liquidity
Exit Reality
Holding period
One-year Reg CF resale restriction; then private sales only.
Exit options
- Acquisition or IPO of the company
- Private sale after one year, if a buyer is found
Secondary market
None on the portal.
Confidence: High
Investment Structures
Regulation Crowdfunding offering (none filed yet)
Securities of a single US life-science company, sold under Section 4(a)(6) through the portal after a Form C is filed: shares, SAFEs, debt, revenue or royalty interests as the issuer chooses; minimums from $500; funds in third-party escrow until the minimum is met; cancellable up to 48 hours before the deadline; one-year resale restrictions; no secondary market on the portal. As of November 9, 2026 only testing-the-waters listings are shown, both proposing SAFEs.
Risk
Risk Structure
This is where the marketplace pitch gives way to the actual operating reality: delayed exits, limited disclosure, fee drag, and path-dependent outcomes.
No track record
No offering has been filed or closed through the portal, so its screening, pricing and follow-up have not yet been applied to a filed offering.
Early-stage drug risk
Both listed companies are preclinical in the US; most drug candidates at this stage never reach approval, and timelines run many years.
Illiquidity
Reg CF securities cannot be freely resold for a year and have no market on the portal; biotech exits usually take longer.
Issuer-paid portal
The portal may take securities of the issuers it lists; the terms appear only in each Form C.
Nothing to judge the portal by
Since its June 2026 launch the portal has not hosted a filed offering.
Why it matters
Investors in its first offerings will be the first test of its diligence, escrow handling and issuer follow-up.
Mitigation / verification
Read each Form C in full on EDGAR, including the portal's compensation and any securities it receives.
Biotech failure rates
Early drug programs usually fail or take a decade or more.
Why it matters
Small checks in single preclinical companies are likely to be lost or locked up for many years.
Mitigation / verification
Size positions accordingly; check the company's cash runway and the next funding it will need.
Portal continuity
The parent reported $275,000 of convertible debt raised.
Why it matters
A portal that closes leaves issuers' updates and investor records to be moved elsewhere.
Mitigation / verification
Keep copies of subscription agreements and the issuer's contact for annual reports.
Biggest Misconceptions & What Actually Happens
- 'Testing the Waters (EOIs)': expressions of interest are non-binding and no money is accepted.
- 'Proposed Raise: $1M (SAFE...)': preliminary terms; the security, cap, discount and minimums become binding only in a filed Form C.
- '$3,141' referral reward: paid only after a referred company files a Form C, launches and stays live and in good standing for 90 days.
- 'Phase I in Canada': the founders' earlier five-patient pilot study, proof of concept for the platform, not a trial by Glafabra; the company's US program is preclinical.
- 'FDA Orphan Drug Designation': a regulatory status for rare-disease programs; it does not mean the therapy is safe, effective or approved.
- 'PawNoma Bio': a fictional demo company.
Regulatory & Legal Posture
Security Status
Securities of each issuer, sold under Section 4(a)(6) (Regulation Crowdfunding) through an SEC-registered funding portal.
BioTech Funding Portal LLC is registered with the SEC as a funding portal and is a FINRA member (#334156); it is not a broker-dealer or investment adviser and gives no recommendations.
Disclosure Quality
Detailed terms and FAQs; per-offering disclosure will be in each Form C, none filed yet.
Custody Model
Investor funds held in third-party escrow until an offering's minimum is met, then released to the issuer; returned in full if not.
Regulatory Backing
North Capital Private Securities Corporation named as escrow agent on the portal's registration.
Tax Treatment
Reporting
Depends on the security (investor FAQ: K-1 or 1099-INT, for example).
Not stated.
Income Character
Capital gain or loss on equity at exit; interest for debt securities.
Reg CF investors hold the issuer's security directly; tax treatment follows that security.
Limitation
No offering is live; confirm treatment from the Form C.
Account Suitability
Taxable
Yes.
Roth IRA
Possible through a self-directed IRA.
Traditional IRA
Possible through a self-directed IRA.
HSA
Not typical.
Before You Invest
Get BioTech Funding Portal investor insights before you invest
K-1 timing, distribution updates, yield insights, and risk signals for BioTech Funding Portal and similar platforms.
- Weekly platform research focused on tax timing and liquidity reality.
- Signals on distributions, risks, and structural tradeoffs before capital is locked up.
- Coverage of adjacent platforms so you can compare better options faster.
Get weekly platform signals
Track fee changes, liquidity updates, risk flags, and adjacent platforms before you invest.
Independent intelligence from AltStreet. No hype. No sponsor spin.
AltStreet Data Layer
What the data actually shows
AltStreet read the portal's registration and amendments, searched EDGAR for every filing that names it, captured its site and dialogs, and checked the two listed companies against outside records.
No offering since launch
No Form C names the portal through November 9, 2026; the CFPORTAL was filed November 2024 and the public launch announced June 22, 2026.
What this means
There is nothing to buy yet and no record to judge.
Two real listings, one demo
Glafabra (orphan-designated Fabry cell therapy; proposed $1M SAFE, $12M cap, 20% discount) and Energesis (preclinical obesity; proposed $1M CrowdSAFE, $13M-$15M cap or 20% discount) are testing the waters; PawNoma Bio is fictional.
What this means
The terms are preliminary and expressions of interest are non-binding; wait for the Form C.
Fees may be paid in stock
The registration allows the portal to be paid 'in cash and/or securities of the issuer'.
What this means
Check each Form C for the portal's stake.
Data as of 2026-11-10 . AltStreet review evidence layer . Public-source analysis
Full dataset0
Offerings filed through the portal
No Form C names it, November 2024 to November 9, 2026.
2
Companies Testing the Waters
Glafabra and Energesis; interest only, no money accepted.
$0
Portal fee to investors
Pass-through costs only, such as 3.5% for card payments.
#334156
FINRA funding portal number
SEC-registered since November 8, 2024; escrow with North Capital.
Decision Fit
Investor Fit
Who this works for, who it does not, and what level of patience and complexity tolerance the platform really demands.
Retail investors who want small, long-term stakes in specific biotech programs and can afford to lose them
The model fits, but there is nothing to buy yet and no record of past offerings.
Investors who need liquidity or income
Reg CF securities in pre-revenue drug developers pay nothing and cannot be sold easily.
Patients and advocates following a specific disease program
The trackers and Q&A are informative; an investment decision should rest on the Form C.
Tradeoffs
Key Tradeoffs
The attraction of pre-IPO access is real, but every benefit comes bundled with a corresponding liquidity, transparency, or pricing cost.
Specialist focus vs. no record
A portal built for biotech, with no offering yet to show how it works in practice.
Retail access vs. drug-development risk
Anyone can invest from $500 once offerings open, in companies that usually take a decade or fail.
No investor fee vs. issuer-paid model
Investors pay nothing directly; the portal is paid by issuers, possibly in their stock.
Avoid
Who This Is Not For
This section should be read as a filter, not an afterthought. If you need income, simplicity, or near-term access to capital, the structure is working against you.
Investors who want to invest now
No offering is live.
Income or liquidity seekers
Early biotech securities pay nothing and are hard to sell.
Investors who need a platform track record
No offering has been filed through the portal since its June 2026 launch.
Editorial View
AltStreet Perspective
The compressed version of the review: what matters, what marketing tends to obscure, and how we would frame the platform for a serious allocator.
Verdict
A registered biotech crowdfunding portal with two proposed raises and no live offering yet.
Positioning
Follow the listings; invest only after reading a filed Form C, including the portal's compensation.
The Bottom Line
biotech.fund: a FINRA-registered biotech portal with two proposed $1M SAFE raises, still at the testing-the-waters stage.
Action
Next Steps
If you still want to engage after reading the review, these are the practical next moves that reduce avoidable mistakes.
Watch EDGAR for the first Form C naming BioTech Funding Portal.
When an offering opens, read the Form C's security, valuation, use of proceeds and the portal's compensation.
Check each company's cash runway and the next clinical milestone it is funding.
AltStreet Research Desk
About to invest in BioTech Funding Portal, or in an offering we haven't covered?
Commission an independent diligence report: the same filing-based analysis behind this review, applied to the specific investment in front of you before you wire the money.
- Built from primary sources: SEC filings, court records, capital structure, and marketing-versus-filings comparison.
- From $750; full reports from $1,495. Fixed price confirmed up front, delivery in 3-5 business days.
- Independent by design: we work for investors and accept no compensation from the companies we cover.
Want this on every new deal, not one? Deal Intelligence sends the alert the day a new offering appears on a covered platform and follows with an analyst-approved investment committee memo.
Deal Intelligence →Appendix
Sources, Disclosures, and Supporting Context
The lower section is structured like a report appendix: relationship context first, adjacent reading second, and evidence last.
Report Appendix
Disclosure
Relationship and compensation context
+
Report Appendix
Disclosure
Relationship and compensation context
Report Appendix
Related Resources
Adjacent platform comparisons, frameworks, and category links
+
Report Appendix
Related Resources
Adjacent platform comparisons, frameworks, and category links
Further Reading
Related Resources
Adjacent frameworks and reviews that help place the platform in a broader allocation or due-diligence context.
Explore Asset Class
Biotech / Early-Stage Life Science EquityReport Appendix
Evidence & Methodology
16 cited passages on file; sources, scope, and how the review was assembled
+
Report Appendix
Evidence & Methodology
16 cited passages on file; sources, scope, and how the review was assembled
Evidence on file
16 supporting passages on file for BioTech Funding Portal and its offerings from 10 source documents, 4 discrepancies flagged. Each passage records the metric it supports, the value read from the document, the page, and the verbatim text where the document has it. Terminal subscribers read the passages; open them in the terminal.
- Cited passages
- 16
- Source documents
- 10
- Analyst verified
- 0
- Discrepancies flagged
- 4
ASReview Evidence
Methodology
Firecrawl captures of biotech.fund pages and its pop-up dialogs (opened one by one); CFPORTAL and amendments and the parent's Form D read from XML; EDGAR full-text and company searches; CourtListener RECAP; outside records on Glafabra (company releases and coverage of its orphan designation, ClinicalTrials.gov number and publication cited on the listing) and Energesis (Akston Biosciences SEC filings, NIH grant records, earlier coverage). No account was opened.
Scope
BioTech Funding Portal LLC and BioTech Social, Inc.; the listings shown on November 9, 2026.
Key Findings
- *Investor FAQ: 'During a Test the Waters (TTW) phase, you can express interest in a company (EOI), but you cannot invest and no funds are collected.'
- *CFPORTAL/A: 'The Funding Portal may charge issuers commissions and other fees payable in cash and/or securities of the issuer based upon the securities offered.'
- *Investor FAQ: 'BFP does not charge fees to investors directly for investing.'
- *Glafabra listing: 'Proposed Raise: $1M (SAFE: 20% discount + $12M Cap)'; Energesis listing: 'Proposed Raise: $1M (CrowdSAFE: Better of $13M-$15M cap or 20% discount)'
- *Referral page: 'After 90 days live and in good standing, BFP pays your $3,141 reward'
- *PawNoma Bio listing: 'Demo profile only. PawNoma Bio is fictional and is shown for educational purposes only.'
- *Terms 3.4: 'BFP does not operate or facilitate a secondary market for these securities.'
Primary Source Pages
FAQ
Frequently Asked Questions
High-intent search questions answered directly, without making users hunt through the full review.
What is BioTech Funding Portal?
A Regulation Crowdfunding portal at biotech.fund for US life-science companies, run by BioTech Funding Portal LLC of Chicago, a subsidiary of BioTech Social, Inc. It is registered with the SEC and is a FINRA member (#334156).
Can I invest on biotech.fund now?
Not yet. As of November 9, 2026 its two real listings, Glafabra Therapeutics and Energesis Pharmaceuticals, are Testing the Waters, where you can only submit a non-binding expression of interest and no money is accepted. Both show proposed terms (a $1 million SAFE raise each), which are preliminary until a Form C is filed. No company has filed a Form C through the portal.
Is biotech.fund legit?
It is a registered funding portal with third-party escrow and no disciplinary history on its registration, and AltStreet found no case or regulatory action naming it. It has no track record: no offering has been filed through it since its June 2026 launch.
Do I need to be accredited?
No. Reg CF offerings are open to anyone 18 or older; non-accredited investors are subject to annual limits based on income and net worth across all crowdfunding portals.
What fees do investors pay?
The portal says it charges investors nothing directly, though vendor costs such as a 3.5% credit card fee may be passed through. Issuers pay the portal in cash and/or their own securities, as stated in each Form C.
What is Glafabra?
Glafabra Therapeutics is developing GT-GLA-S03, a one-time cell therapy for Fabry disease that uses a patient's own modified stem cells; it received FDA Orphan Drug Designation in March 2026. Its founders ran a five-patient pilot study in Canada, proof of concept for the platform; the company's US program is preclinical, with an IND targeted for mid-2027 and a trial start in early 2028 per its website. On the portal it proposes a $1 million SAFE raise at a $12 million cap and 20% discount.
What is Energesis?
Energesis Pharmaceuticals, of Cambridge, Massachusetts, is developing oral obesity drugs that increase brown fat and energy expenditure; its lead, EGS-2632, combines two previously approved drugs and is listed as preclinical. On the portal it proposes a $1 million CrowdSAFE raise at 'the better of a $13M-$15M cap or 20% discount'.
How does the $3,141 referral reward work?
The portal pays $3,141 to a person who refers a company, but only after the company signs a posting agreement, files a Form C through the portal, launches its offering and stays live and in good standing for 90 days. A listing alone does not trigger payment.
Can I sell a crowdfunding investment from the portal?
Reg CF securities cannot be freely resold for one year, and the portal does not run a secondary market; after that, sales are private and buyers are scarce.